関節リウマチ、乾癬性関節炎、強直性脊椎炎を対象とした１５０００人年におよぶウパダシチニブの安全性
RMD Open. 2023;9(1):e002735 doi: 10.1136/rmdopen-2022-002735
Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.